New drug ESG406 enters human trials for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new drug called ESG406 in adults (ages 18-80) with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for any tumor sh…
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 13:09 UTC